Galectin Therapeutics(GALT) - 2023 Q4 - Annual Results

Exhibit 99.1 Galectin Therapeutics Reports 2023 Financial Results and Provides Business Update NORCROSS, Ga., March 29, 2024 (GLOBE NEWSWIRE) – Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results and provided a business update for the year ended December 31, 2023. Joel Lewis, Chief Executive Officer and President of Galectin Therapeutics, said "We have been focused on advancing our Metabolic Dysfunction-Associated ...